Haisco Pharma Gets Nod for Myasthenia Gravis Drug Trial

MT Newswires Live

Nov 04

Haisco Pharmaceutical Group (SHE:002653) has received approval from China's National Medical Products Administration to proceed with clinical trials for a new indication of its novel drug, HSK39297 tablets.

The approval is for the use of HSK39297 tablets to treat Generalized Severe Myasthenia Gravis (GMG), a rare autoimmune disease that causes systemic muscle weakness. GMG was recognized as a rare disease in China in 2018.

Haisco said current targeted treatments for GMG in China are primarily inconvenient injected biologics, which can affect patient compliance.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2580772562"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2580772562\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2580772562?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-04 12:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2580772562","market":"sh","top_or_hot":-1,"title":"Haisco Pharma Gets Nod for Myasthenia Gravis Drug Trial","media":"MT Newswires Live","content":"<html><body><p> Haisco Pharmaceutical Group (SHE:002653) has received approval from China's National Medical Products Administration to proceed with clinical trials for a new indication of its novel drug, HSK39297 tablets.</p><p>The approval is for the use of HSK39297 tablets to treat Generalized Severe Myasthenia Gravis (GMG), a rare autoimmune disease that causes systemic muscle weakness. GMG was recognized as a rare disease in China in 2018.</p><p>Haisco said current targeted treatments for GMG in China are primarily inconvenient injected biologics, which can affect patient compliance.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Haisco Pharma Gets Nod for Myasthenia Gravis Drug Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHaisco Pharma Gets Nod for Myasthenia Gravis Drug Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-11-04 12:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Haisco Pharmaceutical Group (SHE:002653) has received approval from China's National Medical Products Administration to proceed with clinical trials for a new indication of its novel drug, HSK39297 tablets.</p><p>The approval is for the use of HSK39297 tablets to treat Generalized Severe Myasthenia Gravis (GMG), a rare autoimmune disease that causes systemic muscle weakness. GMG was recognized as a rare disease in China in 2018.</p><p>Haisco said current targeted treatments for GMG in China are primarily inconvenient injected biologics, which can affect patient compliance.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0028","symbol_name":"国家队","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2580772562","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2580772562","pubTimestamp":1762228960,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Haisco Pharmaceutical Group  has received approval from China's National Medical Products Administration to proceed with clinical trials for a new indication of its novel drug, HSK39297 tablets.The approval is for the use of HSK39297 tablets to treat Generalized Severe Myasthenia Gravis , a rare autoimmune disease that causes systemic muscle weakness. GMG was recognized as a rare disease in China in 2018.Haisco said current targeted treatments for GMG in China are primarily inconvenient injected biologics, which can affect patient compliance.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK0028":"国家队","BK7099":"工业房地产投资信托","GMG.AU":"GOODMAN GROUP","BK0239":"医药制造","002653":"海思科","BK7510":"REITs概念","BK0188":"融资融券","BK0033":"西藏振兴","BK7155":"工业房地产信托","BK0077":"质押式回购"},"translate_title":"海思科制药重症肌无力药物试验获批","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"002653":0.9,"GMG.AU":1},"content_text":"Haisco Pharmaceutical Group (SHE:002653) has received approval from China's National Medical Products Administration to proceed with clinical trials for a new indication of its novel drug, HSK39297 tablets.The approval is for the use of HSK39297 tablets to treat Generalized Severe Myasthenia Gravis (GMG), a rare autoimmune disease that causes systemic muscle weakness. GMG was recognized as a rare disease in China in 2018.Haisco said current targeted treatments for GMG in China are primarily inconvenient injected biologics, which can affect patient compliance.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}